SEARCH:   Advanced

Blood, 15 July 2006, Vol. 108, No. 2, pp. 441-451. Prepublished online as a Blood First Edition Paper on March 23, 2006; DOI 10.1182/blood-2005-07-3011. This Article Full Text (PDF) All Versions of this Article: 2005-07-3011v1 108/2/441    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hilden, J. M Articles by Reaman, G. H Search for Related Content PubMed PubMed Citation Articles by Hilden, J. M Articles by Reaman, G. H Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 27, 2005 Accepted March 3, 2006 CCG 1953: acute lymphoblastic leukemia in infants: analysis of prognostic factors. A report from the Children's Oncology Group Joanne M Hilden*, Patricia A Dinndorf, Sharon O Meerbaum, Harland Sather, Doojduen Villaluna, Nyla A Heerema, Ron McGlennen, Franklin O Smith, William G Woods, Wanda L Salzer, Helen S Johnstone, Zoann Dreyer, and Gregory H Reaman The Children's Hospital at The Cleveland Clinic, Cleveland, OH, USA Children's National Medical Center, Washington, DC, USA Children's Oncology Group Operations Center, Arcadia, CA, USA Columbus Children's Hospital, Columbus, OH, USA University of Minnesota, Minneapolis, MN, USA Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, OH, USA Children's Healthcare of Atlanta, Atlanta, GA, USA Keesler Medical Center, Keesler AFB (Biloxi), MS, USA University of Illinois, Chicago, IL, USA Texas Children's Cancer Center at Baylor College of Medicine, Houston, TX, USA Children's National Medical Center, Washington, DC, USA; Children's Oncology Group Operations Center, Arcadia, CA, USA * Corresponding author; email: hildenj{at}ccf.org. Infant ALL has a poor therapeutic outcome despite attempts to treat it based on prognostic factor-guided therapy. This is the first cooperative group trial characterizing all infants at the molecular level for MLL/11q23 rearrangement. All infants enrolled on CCG 1953 were tested for MLL rearrangement by Southern Blot, and the 11q23 translocation partner identified (4;11, 9;11, 11;19, or "other") by reverse-transcriptase PCR. 115 infants enrolled; overall event-free survival (EFS) was 41.7% (SD = 9.2%) and overall survival (OS) was 44.8% at 5 years. Five-year EFS for MLL rearranged cases was 33.6%, and for MLL non-rearranged cases was 60.3%. The difference in EFS between the three major MLL rearrangements did not reach statistical significance. Multivariate Cox regression analyses showed a rank order of significance for negative impact on prognosis of CD10 negativity, age less than 6 months, and MLL rearrangement, in that order. Toxicity was the most frequent cause of death. Relapse as a first event in 1953 was later (median 295 days) compared to 1883 historical control (median 207 days). MLL/11q23 rearrangement, CD10 expression, and age are important prognostic factors in infant ALL, but molecular 11q23 translocation partners do not predict outcome. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C.-H. Pui Central Nervous System Disease in Acute Lymphoblastic Leukemia: Prophylaxis and Treatment Hematology, January 1, 2006; 2006(1): 142 - 146. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020